(1-methyl-1,2,3,4-tetrahydroquinolin-2-yl)methanamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (1-methyl-1,2,3,4-tetrahydroquinolin-2-yl)methanamine
• 英文别名: (1-methyl-3,4-dihydro-2H-quinolin-2-yl)methanamine
• 化学式: C₁₁H₁₆N₂
• 分子量: 176.261
• InChiKey: BQMBBKZALPGTHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1-methyl-1,2,3,4-tetrahydroquinolin-2-yl)methanamine 、 异硫氰酸乙酯 以 二氯甲烷 为溶剂， 反应 16.0h， 生成 1-ethyl-3-[(1-methyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl]thiourea
  参考文献：
  名称：

  Highly Potent and Selective MT₂ Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines

  摘要：

  Molecular superposition models guided the design of novel melatonin receptor ligands characterized by a 2-acylaminomethyltetrahydroquinoline scaffold. Starting from the structure of N-anilinoethylamide ligands, the flexible chain was conformationally constrained to reproduce the bioactive conformation of melatonin. Structure activity relationships were investigated, focusing on the substituent at the nitrogen atom, the position of the methoxy group, and the replacement of the amide side chain by urea and thiourea groups. The compounds were tested for binding affinity and intrinsic activity at human MT1, and MT2 receptors. Structural optimization resulted in N-[(1-benzyl-1,2,3,4-tetrahydro-5-methoxyquinolin-2-yl)methyl]propionamide (UCM1014), with picomolar MT2 binding affinity (K-i = 0.001 nM), more than 10000-fold selectivity over the MT1 receptor, and a full agonist profile (GTP gamma S test), being the most potent MT2-selective full agonist reported to date. Molecular dynamics simulations provided a rationale for high binding affinity, stereoselectivity, and agonist behavior of these novel melatonin receptor ligands based on superposition models and conformational preference.

  DOI：

  10.1021/acs.jmedchem.5b01066
• 作为产物：
  描述：

  N-((1,2,3,4-tetrahydroquinolin-2-yl)methyl)benzamide 在 盐酸 、 氢氧化钾 作用下， 生成 (1-methyl-1,2,3,4-tetrahydroquinolin-2-yl)methanamine
  参考文献：
  名称：

  死于1-Benzoyl-2-cyan-1,2-dihydrochinolin的Hydrierung von。（Reissert'scherKörper）我

  摘要：

  DOI：

  10.1002/hlca.19370200128

文献信息

• ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF
  申请人：Bayburt Erol K.

  公开号：US20080153871A1

  公开（公告）日：2008-06-26

  The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar 1 , L 1 , R 1 , R 2 , R 3 , R 4 , R 5 , Y 1 , Y 2 , and Y 3 , are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.

  本申请涉及的化合物是TRPV1拮抗剂，其化学式为（I），其中变量Ar1，L1，R1，R2，R3，R4，R5，Y1，Y2和Y3如描述中所定义，对于治疗由辣椒素受体活性引起或加剧的疾病是有用的。
• [EN] PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS PHTALAZINE DE FORMULE (I) UTILISÉS COMME INHIBITEURS DE LA PCAF ET DE LA GCN5 DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER
  申请人：GENENTECH INC

  公开号：WO2016036954A1

  公开（公告）日：2016-03-10

  The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R1, R3, R4, R5, and each Re have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.

  本发明涉及使用式(I)的化合物或其药学上可接受的盐治疗由PCAF和GCN5介导的疾病的方法：其中环A、R1、R3、R4、R5和每个Re具有规范中定义的任何值。还包括式(I)的新化合物及其盐，以及包含式(I)的化合物或其药学上可接受的盐的药物组合物。
• Antagonists of the TRPV1 receptor and uses thereof
  申请人：Abbott Laboratories

  公开号：EP2450346A1

  公开（公告）日：2012-05-09

  The present application is directed to compounds that are TRPV1 antagonists and have formula(I): wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.

  本申请涉及作为 TRPV1 拮抗剂并具有式（I）的化合物：其中变量 Ar1、L1、R1、R2、R3、R4、R5、Y1、Y2 和 Y3 如描述中所定义，这些化合物可用于治疗由香草素受体活性引起或加剧的疾病。
• Therapeutic compounds and uses thereof
  申请人：GENENTECH, INC.

  公开号：US10155764B2

  公开（公告）日：2018-12-18

  The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R1, R3, R4, R5, and each Re have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.

  本发明涉及使用式（I）化合物或其药学上可接受的盐治疗 PCAF 和 GCN5 介导的疾病的方法： 其中环 A、R1、R3、R4、R5 和各 Re 具有说明书中定义的任一值。还包括新型的式 (I) 化合物及其盐，以及包含式 (I) 化合物或其药学上可接受的盐的药物组合物。
• Neue Derivate des 2-Aminomethyl-tetrahydro-chinolins und -tetrahydro-isochinolins
  作者：Alois Gassmann、H. Rupe

  DOI：10.1002/hlca.193902201159

  日期：——